MKI67 and neoplasm: The results of this study also indicate that long-term treatment with lanreotide autogel/depot 120 mg every 4 weeks has sustained anti-tumour effects in patients with non-functioning metastatic grade 1 or 2 (Ki-67 < 10%) enteropancreatic NETs, irrespective of tumour origin.